ALDEYRA THERAPEUTICS, INC. (NASDAQ:ALDX) Files An 8-K Other Events
ITEM8.01.
| OTHER EVENTS. |
On February17, 2017, Aldeyra Therapeutics, Inc. (Aldeyra)
announced that it completed the previously announced underwritten
public offering of its common stock. Aldeyra sold 2,555,555
shares of its common stock, including 333,333 shares sold in
connection with the exercise in full by the underwriters of their
option to purchase additional shares. The net proceeds of the
offering, including the exercise of the option, were
approximately $10.5 million, after deducting the underwriting
discounts and commissions and the other estimated offering
expenses payable by Aldeyra.
A copy of the press release is attached hereto as Exhibit99.1 to
this Current Report on Form 8-K and is incorporated herein by
reference.
| ITEM9.01. | FINANCIAL STATEMENTS AND EXHIBITS. |
(d)Exhibits.
|
ExhibitNo. |
Description |
|
| 99.1 |
Press Release of Aldeyra Therapeutics, Inc., dated February 17, 2017. |
About ALDEYRA THERAPEUTICS, INC. (NASDAQ:ALDX)
Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company’s aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency. ALDEYRA THERAPEUTICS, INC. (NASDAQ:ALDX) Recent Trading Information
ALDEYRA THERAPEUTICS, INC. (NASDAQ:ALDX) closed its last trading session up +0.15 at 5.10 with 11,366 shares trading hands.